| Autor: |
Menon, A.P. (Ashwathi Puravankara), Moreno, B. (Beatriz), Meraviglia-Crivelli, D. (Daniel), Nonatelli, F. (Francesca), Villanueva-Ruiz, M.E. (María Elena), Barainka, M. (Martin), Zheleva, A. (Angelina), van-Santen, H.M. (Hisse M.), Pastor, F. (Fernando) |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Popis: |
Simple Summary CD3 complex provides the first signal sensed by the TCR of the lymphocyte to trigger its activation. Thus, it becomes a very attractive receptor to determine the fate of the immune response in different contexts from tolerance induction to immune activation. We discuss CD3-TCR complex assembly and the current and emerging approaches to harvest CD3 activity for immunotherapy. Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB. Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the first signal that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation. While the mechanisms through which antigen sensing and signal transduction occur in the CD3-TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3-TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3-TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3-TCR function for potentiating cancer immunotherapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
